{
  "title": "What this review means",
  "includeSubclaimIllustrations": false,
  "redteamReviewed": true,
  "accessNotice": "Source checking used bounded original primary abstract passages/status records and selected original partial-body passages. No complete-abstract or complete-paper audit, or independent scientific peer review, is claimed. Detailed access counts and limitations appear in the review.",
  "overview": "Rapamycin has strong animal longevity evidence, but intermittent dosing has not yet established improved physical function in otherwise healthy older adults.",
  "implications": "Preregistered primary-subclaim aggregation returns SC2Γ. Strong preclinical biology and selected exploratory human signals coexist with a directly relevant negative-direction functional primary null. Markers, body composition and other-indication clinical results do not identify sustained physical-function benefit for the registered regimen and population. This scores the stated positive proposition without a preset verdict or safety recommendation.",
  "limitations": "55 primary reports with 3 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness. The grade applies to the exact registered claim; stronger findings for narrower subclaims remain separate. No complete-paper audit or blinded calibration is claimed. This educational review does not establish an individual treatment recommendation."
}